Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Exelixis, Inc. < Previous 1 2 3 4 Next > Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor January 06, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma January 05, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022 January 04, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer January 04, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Elects Jacqueline Wright to Its Board of Directors December 17, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors December 15, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021 November 20, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer November 09, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December November 03, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update November 02, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021 October 19, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes October 14, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma October 14, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021 September 20, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021 September 18, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer September 17, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021 September 16, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Statement on the Passing of Two Senior Executives September 06, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September September 01, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma August 25, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology August 16, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update August 05, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer August 05, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021 July 22, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021 July 08, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence June 18, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors June 14, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma June 04, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021 June 04, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma June 04, 2021 From Exelixis, Inc. Via Business Wire Tickers EXEL < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.